6533b830fe1ef96bd1297bcc

RESEARCH PRODUCT

Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study

Nassim MatinGiovanni CorselloCatia RomanoRiccardo LubranoGiovanna VitalitiNazgol Motamed-gorjiPiero PavoneLaura MauceriRaffaele Falsaperla

subject

Pediatricsmedicine.medical_specialtyEfficiency and safety; levetiracetam; neonatal seizures; prospective studyNeonatal intensive care unitlevetiracetamneonatal seizuresAnticonvulsant therapyNO03 medical and health sciences0302 clinical medicine030225 pediatricsMedicineIn patientProspective cohort studybusiness.industryGeneral NeuroscienceEfficiency and safetyFirst line treatmentEfficiency and safety; levetiracetam; neonatal seizures; prospective study;AnesthesiaPediatrics Perinatology and Child HealthOriginal Articleneonatal seizureLevetiracetambusiness030217 neurology & neurosurgerymedicine.drugprospective study

description

Aim of the Study: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first-line treatment of neonatal seizures. Materials and Methods: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. Results: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regarding safety of LEV, no major side-effects were observed. Conclusions: To our knowledge, it is one of the few studies confirming the efficiency of LEV as first-line treatment in seizures of this age group. LEV was effective in resolving seizures and was safely administered in the current study.

yearjournalcountryeditionlanguage
2017-05-30
10.4103/jpn.jpn_172_16http://hdl.handle.net/10447/416414